More News! 5 Jan 2017 Investors Jump on Hypersensitivity Peptides from GSK Spinout Neurokinins are under investigation for a range of conditions from women’s health to pain. NeRRe gets a boost for its programs. Neurotransmitting peptides just got a cash injection from Forbion,… January 5, 2017 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 19 Jan 2023 Cloned maggot enzyme wound treatment moves closer to reality Cambridge U.K. biotech company SolasCure, which is developing a wound cleaning technology, has published its pre-clinical results with the International Wound Journal, showing preliminary evidence that supports its new enzymatic… January 19, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 16 Oct 2017 New Stem Cells Could Take Cell Research and Therapies to the Next Level British researchers have created a new type of stem cell in mice. It has even greater potential than current cell lines in research and in the clinic. Stem cells have… October 16, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 1 Oct 2025 Merck backs out of Britain: is the U.K. struggling to retain its life sciences sector? The U.K. has had a stronghold on the biopharma and healthcare industry for a long time and remains one of the top hubs for life science research. So, Merck’s decision… October 1, 2025 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 3 Feb 2023 UK approval for AbbVie Crohn’s disease drug AbbVie has announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved RINVOQ (upadacitinib), a janus kinase (JAK) inhibitor, for the treatment of adult patients with moderately… February 3, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jun 2018 Cambridge Biotech Raises €32M Series A Round to Treat Chronic Inflammation NodThera raised £28M (€32M) in a Series A round co-led by Sofinnova Partners and 5AM Ventures to develop treatments for chronic inflammation. NodThera, based in Cambridge, UK, closed a substantial… June 25, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 14 Sep 2022 New study reveals first genetic links in ME and chronic fatigue syndrome For the first time in more than 30 years, replicable genetic findings have been reported in the study into myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). UK-based PrecisionLife today (September 14) unveiled… September 14, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 13 Nov 2017 British Biotech Gets PRIME Designation for its Brittle Bones Drug The EMA has awarded PRIME Designation to Mereo BioPharma’s osteogenesis imperfecta drug, a condition for which there is no treatment on the market. Mereo acquires, develops and commercializes therapies for… November 13, 2017 - 1 minutemin - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jan 2022 Sanofi Joins AI Gold Rush in €4.6B Drug Discovery Pact with Exscientia As big pharma companies flock to drug discovery collaborations with artificial intelligence (AI) firms, the French giant Sanofi has sealed a €4.6B deal with the UK AI player Exscientia to… January 11, 2022 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jun 2017 LAB282 Awards Second Funding Round to 5 Academic Projects at Oxford Evotec and the University of Oxford have announced the academic projects that will receive a financial award to push them towards launching spin-outs. LAB282 is a partnership between the German… June 22, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 13 Nov 2017 Biotech Unicorn’s T-Cell Receptor Therapy “Nearly Doubles” Survival in Uveal Melanoma Immunocore, one of the only three European biotech unicorns, has presented Phase I results for its TCR immunotherapy IMCgp100 in patients suffering from metastatic uveal melanoma. Results are positive, but… November 13, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 11 Nov 2019 Mereo BioPharma’s Brittle Bone Disease Drug Stumbles in Phase II The lead drug of the UK company Mereo BioPharma has achieved mixed results in a phase IIb trial in adults with the genetic condition osteogenesis imperfecta, also known as brittle… November 11, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email